New perspectives on CKD-induced dyslipidemia

Abstract INTRODUCTION: Chronic kidney disease (CKD) is a world-wide health concern associated with a significantly higher cardiovascular morbidity and mortality. One of the principal cardiovascular risk factors is the lipid profile. CKD patients have a more frequent and progressive atheromatous dise...

Descripción completa

Detalles Bibliográficos
Autores: Bermúdez López, Marcelino, Arroyo, David, Betriu i Bars, M. Àngels, Masana, Luis, Fernández i Giráldez, Elvira, Valdivielso Revilla, José Manuel
Tipo de recurso: artículo
Estado:Versión aceptada para publicación
Fecha de publicación:2017
País:España
Institución:Universitat de Lleida (UdL)
Repositorio:Repositori Obert UdL
OAI Identifier:oai:repositori.udl.cat:10459.1/63143
Acceso en línea:https://doi.org/10.1080/14728222.2017.1369961
http://hdl.handle.net/10459.1/63143
Access Level:acceso abierto
Palabra clave:Atherosclerosis
Cardiovascular disease
Chronic kidney disease
Dyslipidemia
Lipoproteins
id ES_5fdefeab21db37124ab5331b599c8a9f
oai_identifier_str oai:repositori.udl.cat:10459.1/63143
network_acronym_str ES
network_name_str España
repository_id_str
spelling New perspectives on CKD-induced dyslipidemiaBermúdez López, MarcelinoArroyo, DavidBetriu i Bars, M. ÀngelsMasana, LuisFernández i Giráldez, ElviraValdivielso Revilla, José ManuelAtherosclerosisCardiovascular diseaseChronic kidney diseaseDyslipidemiaLipoproteinsAbstract INTRODUCTION: Chronic kidney disease (CKD) is a world-wide health concern associated with a significantly higher cardiovascular morbidity and mortality. One of the principal cardiovascular risk factors is the lipid profile. CKD patients have a more frequent and progressive atheromatous disease that cannot be explained by the classical lipid parameters used in the daily clinical practice. Areas covered: The current review summarizes prevailing knowledge on the role of lipids in atheromathosis in CKD patients, including an overview of lipoprotein metabolism highlighting the CKD-induced alterations. Moreover, to obtain information beyond traditional lipid parameters, new state-of-the-art technologies such as lipoprotein subfraction profiling and lipidomics are also reviewed. Finally, we analyse the potential of new lipoprotein subclasses as therapeutic targets in CKD. Expert opinion: The CKD-induced lipid profile has specific features distinct from the general population. Besides quantitative alterations, renal patients have a plethora of qualitative lipid alterations that cannot be detected by routine determinations and are responsible for the excess of cardiovascular risk. New parameters, such as lipoprotein particle number and size, together with new biomarkers obtained by lipidomics will personalize the management of these patients. Therefore, nephrologists need to be aware of new insights into lipoprotein metabolism to improve cardiovascular risk assessment.This work was supported by the intramural program of the IRBLleida, Instituto de Salud Carlos III (RETIC RD16/0009/0011, FIS PI16/01354) and FEDER funds.Taylor & Francis2017info:eu-repo/semantics/articleinfo:eu-repo/semantics/acceptedVersionapplication/pdfhttps://doi.org/10.1080/14728222.2017.1369961http://hdl.handle.net/10459.1/63143reponame:Repositori Obert UdL instname:Universitat de Lleida (UdL)InglésVersió postprint del document publicat a: https://doi.org/10.1080/14728222.2017.1369961Expert Opinion on Therapeutic Targets, 2017, vol. 21, núm.10, p. 967-976(c) Taylor & Francis, 2017info:eu-repo/semantics/openAccessoai:repositori.udl.cat:10459.1/631432026-06-24T12:42:17Z
dc.title.none.fl_str_mv New perspectives on CKD-induced dyslipidemia
title New perspectives on CKD-induced dyslipidemia
spellingShingle New perspectives on CKD-induced dyslipidemia
Bermúdez López, Marcelino
Atherosclerosis
Cardiovascular disease
Chronic kidney disease
Dyslipidemia
Lipoproteins
title_short New perspectives on CKD-induced dyslipidemia
title_full New perspectives on CKD-induced dyslipidemia
title_fullStr New perspectives on CKD-induced dyslipidemia
title_full_unstemmed New perspectives on CKD-induced dyslipidemia
title_sort New perspectives on CKD-induced dyslipidemia
dc.creator.none.fl_str_mv Bermúdez López, Marcelino
Arroyo, David
Betriu i Bars, M. Àngels
Masana, Luis
Fernández i Giráldez, Elvira
Valdivielso Revilla, José Manuel
author Bermúdez López, Marcelino
author_facet Bermúdez López, Marcelino
Arroyo, David
Betriu i Bars, M. Àngels
Masana, Luis
Fernández i Giráldez, Elvira
Valdivielso Revilla, José Manuel
author_role author
author2 Arroyo, David
Betriu i Bars, M. Àngels
Masana, Luis
Fernández i Giráldez, Elvira
Valdivielso Revilla, José Manuel
author2_role author
author
author
author
author
dc.subject.none.fl_str_mv Atherosclerosis
Cardiovascular disease
Chronic kidney disease
Dyslipidemia
Lipoproteins
topic Atherosclerosis
Cardiovascular disease
Chronic kidney disease
Dyslipidemia
Lipoproteins
description Abstract INTRODUCTION: Chronic kidney disease (CKD) is a world-wide health concern associated with a significantly higher cardiovascular morbidity and mortality. One of the principal cardiovascular risk factors is the lipid profile. CKD patients have a more frequent and progressive atheromatous disease that cannot be explained by the classical lipid parameters used in the daily clinical practice. Areas covered: The current review summarizes prevailing knowledge on the role of lipids in atheromathosis in CKD patients, including an overview of lipoprotein metabolism highlighting the CKD-induced alterations. Moreover, to obtain information beyond traditional lipid parameters, new state-of-the-art technologies such as lipoprotein subfraction profiling and lipidomics are also reviewed. Finally, we analyse the potential of new lipoprotein subclasses as therapeutic targets in CKD. Expert opinion: The CKD-induced lipid profile has specific features distinct from the general population. Besides quantitative alterations, renal patients have a plethora of qualitative lipid alterations that cannot be detected by routine determinations and are responsible for the excess of cardiovascular risk. New parameters, such as lipoprotein particle number and size, together with new biomarkers obtained by lipidomics will personalize the management of these patients. Therefore, nephrologists need to be aware of new insights into lipoprotein metabolism to improve cardiovascular risk assessment.
publishDate 2017
dc.date.none.fl_str_mv 2017
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/acceptedVersion
format article
status_str acceptedVersion
dc.identifier.none.fl_str_mv https://doi.org/10.1080/14728222.2017.1369961
http://hdl.handle.net/10459.1/63143
url https://doi.org/10.1080/14728222.2017.1369961
http://hdl.handle.net/10459.1/63143
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.relation.none.fl_str_mv Versió postprint del document publicat a: https://doi.org/10.1080/14728222.2017.1369961
Expert Opinion on Therapeutic Targets, 2017, vol. 21, núm.10, p. 967-976
dc.rights.none.fl_str_mv (c) Taylor & Francis, 2017
info:eu-repo/semantics/openAccess
rights_invalid_str_mv (c) Taylor & Francis, 2017
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv application/pdf
dc.publisher.none.fl_str_mv Taylor & Francis
publisher.none.fl_str_mv Taylor & Francis
dc.source.none.fl_str_mv reponame:Repositori Obert UdL
instname:Universitat de Lleida (UdL)
instname_str Universitat de Lleida (UdL)
reponame_str Repositori Obert UdL
collection Repositori Obert UdL
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869409250065776640
score 15,811543

Similares en LA Referencia